Pemvidutide · source year
5 selected, source-linked Pemvidutide records carrying a 2026 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
5 selected records.
1 represented type.
5 distinct public records.
Cited chronology
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07795164 at 2026-09-09T19:17:17.076Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was pemvidutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06987513 at 2026-08-10T18:10:03.928Z. Its registry update date was 2026-07-31, and PeptideScanner's reviewed identity mapping was pemvidutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05989711 at 2026-07-30T16:19:36.923Z. Its registry update date was 2026-05-18, and PeptideScanner's reviewed identity mapping was pemvidutide.
Source: ClinicalTrials.gov ↗
Clinical trials
ClinicalTrials.gov lists a completed Pemvidutide study sponsored by Altimmune, Inc.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07009860 at 2026-07-30T16:22:22.335Z. Its registry update date was 2026-03-20, and PeptideScanner's reviewed identity mapping was pemvidutide.
Source: ClinicalTrials.gov ↗